Staphylococcus Or Streptococcus (e.g., Pneumococcus Or Streptococcus Pneumoniae, Streptococcus Mutans, Etc.) Patents (Class 424/165.1)
  • Patent number: 7687278
    Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of Streptococci mutans by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of Streptococci mutans in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and Streptococci mutans from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: March 30, 2010
    Assignee: GC Corporation
    Inventor: Atsushi Tachino
  • Publication number: 20100015138
    Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.
    Type: Application
    Filed: June 30, 2009
    Publication date: January 21, 2010
    Inventors: Magnus Hook, Ya-Ping Ko, Emanuel Smeds, Yannakambadi K. Ganesh
  • Patent number: 7648830
    Abstract: A method is provided for determining the presence of a target bacteria based on its resistance to a cell lysing antibiotic. Said antibiotic is used to lyse cells of non-target bacteria in a sample and hence facilitate isolation of the target prior to detection by known means.
    Type: Grant
    Filed: September 2, 2002
    Date of Patent: January 19, 2010
    Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland
    Inventors: David James Squirrell, Rachel Louise Leslie, Kevin J Bown
  • Patent number: 7625561
    Abstract: Common oral diseases such as periodontitis and dental caries can be prevented effectively by passive immunization. The present invention provides human single chain Fv (scFv) and diabody antibody fragments based on the binding characteristics of the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivatives bind specifically to SAI/II, the surface adhesin of Streptococcus and the human diabody derivative is capable of aggregating streptococcal cells, making it a useful candidate therapeutic agent for passive immunization against oral diseases.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: December 1, 2009
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Ricarda Finnern, Rainer Fischer
  • Publication number: 20090274704
    Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds a Staphylococcus aureus capsular polysaccharide antigen and a constant region that does not bind staphylococcal protein A.
    Type: Application
    Filed: July 2, 2009
    Publication date: November 5, 2009
    Applicant: STROX Biopharmaceuticals, LLC
    Inventor: Stanley Arthur Kim
  • Patent number: 7588920
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: September 15, 2009
    Assignee: Wyeth
    Inventors: Lynn Doucette-Stamm, David Bush
  • Publication number: 20090162379
    Abstract: Provided herein is a method for identifying small molecule inhibitors of S. aureus SdrD protein attachment to a host cell receptor using a structural model of SdrD protein-receptor interaction. Also provided are the small molecule inhibitors so identified and synthetic small molecules effective to bind SdrD protein and/or the host cell receptor. In addition, antibodies directed against SdrD protein are provided. Further provided are methods of treating or preventing S. aureus associated lung infections and of inhibiting S. aureus adherence to a lung cell using the small molecules and antibodies described herein.
    Type: Application
    Filed: October 1, 2008
    Publication date: June 25, 2009
    Inventors: Magnus Hook, Elena M. Barbu
  • Patent number: 7531633
    Abstract: A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing Staphylococcus infection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: May 12, 2009
    Assignee: Nabi Biopharmaceuticals
    Inventors: Viliam Pavliak, Ali Ibrahim Fattom
  • Publication number: 20090081236
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: April 11, 2008
    Publication date: March 26, 2009
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Publication number: 20090074755
    Abstract: The present invention relates to compositions and methods for treating Staphylococcus aureus (S. aureus) infections. In particular, the present invention provides vaccines comprising a Panton-Valentine Leukocidin (u) antigen, antibodies which bind a PVL antigen and compositions containing the same, methods of making such compositions and methods for treating S. aureus infections, including those that are community acquired methicillin-resistant infections. The present invention also provides PVL antibodies, including PVL antibodies specific for a single PVL subunit, and PVL antigens, including conjugated and mutated PVL antigens.
    Type: Application
    Filed: June 13, 2006
    Publication date: March 19, 2009
    Inventors: Kimberly Louise Taylor, Ali Ibrahim Fattom
  • Publication number: 20090053235
    Abstract: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.
    Type: Application
    Filed: February 27, 2007
    Publication date: February 26, 2009
    Inventors: Kimberly L. Taylor, Ali I. Fattom
  • Publication number: 20090041782
    Abstract: A polynucleotide encoding a polypeptide which lowers the glucose side chain amount in a serotype-specific polysaccharide antigen of Streptococcus mutans; novel Streptococcus mutans strain having the above polynucleotide; an antibody specific to this Streptococcus mutans strain; and a method of detecting the above-described Streptococcus mutans strain occurring in a subject sample. According to this method, it is possible to examine the presence or absence of Streptococcus mutans of an untypable serotype in a subject sample to thereby specify a subject having a high risk of the onset of infective endocarditis.
    Type: Application
    Filed: December 28, 2004
    Publication date: February 12, 2009
    Inventors: Takashi Ooshima, Kazuhiko Nakano
  • Publication number: 20090010929
    Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.
    Type: Application
    Filed: December 4, 2007
    Publication date: January 8, 2009
    Inventors: Michael F. Good, Michael R. Batzloff, Manisha Pandey
  • Publication number: 20080311129
    Abstract: A method for the production of antibodies or microbial adherents administers is disclosed. The antibodies or microbial adherents inhibitors are administered to a patient suffering from strep throat to substantially prevent the adherents of colony-forming immunogens or haptens in the throat of the patient. Application of the antibodies should decrease the colonization of the oropharnyx, and therefore decrease symptoms of the sore inflamed throat and ultimately decrease the need for antibiotics.
    Type: Application
    Filed: November 1, 2007
    Publication date: December 18, 2008
    Applicant: Camas Incorporated
    Inventors: Peter Nash, Bradley M. Mitteness, Michael O'Rourke
  • Patent number: 7438912
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: October 21, 2008
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
  • Publication number: 20080171054
    Abstract: The present invention is concerned with novel antibodies, medicaments, pharmaceutical packs, methods of manufacture of medicaments and methods for the treatment of micro-organism infections, particularly for the treatment of Staphylococcal infections such as S. aureus infections including MRSA infections.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 17, 2008
    Inventors: James Peter Burnie, Ruth Christine Matthews
  • Publication number: 20080171053
    Abstract: A number of immunologically active agents are described, including an isolated protein or polypeptide that includes the amino acid sequence of SEQ ID NO: 1, immunogenic conjugates containing either the protein or polypeptide, a full-length Pneumocystis kexin, or a full length Streptococcus pneumoniae pneumococcal surface protein A (PspA), antibodies recognizing the protein or polypeptide or the immunogenic conjugates (particularly the epitope of SEQ ID NO: 1), and nucleic acid molecules that encode the protein or polypeptide, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a patient.
    Type: Application
    Filed: December 31, 2004
    Publication date: July 17, 2008
    Inventors: Francis Gigliotti, Terry W. Wright, Constantine G. Haidaris, Patricia J. Simpson-Haidaris, Jesse Wells
  • Patent number: 7368112
    Abstract: The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus CIfA protein are described. The nucleic acids encode proteins that can be useful as vaccines or in pharmaceutical compositions for application to prevent infection, promotion of wound healing, blocking adherence to indwelling medical devices, or diagnosis of infection.
    Type: Grant
    Filed: February 7, 2006
    Date of Patent: May 6, 2008
    Assignee: The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin
    Inventors: Timothy James Foster, Damien Leo McDevitt
  • Patent number: 7364738
    Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: April 29, 2008
    Assignee: Inhibitex, Inc.
    Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
  • Patent number: 7316910
    Abstract: A reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular protein. The substrate is nonspecific within the groups of beta-hemolytic streptococcus bacterium and is in contact with an inert solid matrix. Upon reaction between the streptococcus enzymatically activate protein and the substrate, a color change discernable by an unaided human eye results. Extracellular streptococcus protein found in saliva represents a less invasive source of biological fluid for the determination as to whether a host suffers acute pharyngitis.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: January 8, 2008
    Assignee: Kinase Scientific, LLC
    Inventors: Leroy E. Mosher, Craig J. Bell
  • Patent number: 7279162
    Abstract: The invention describes the identification, making, and isolation of immunoglobulin and antigen useful for preventing, diagnosing, and treating staphylococcal infections. The invention further describes an in vivo animal model useful for testing the efficacy of pharmaceutical compositions, including pharmaceutical compositions of immunoglobulin and isolated antigen.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 9, 2007
    Assignee: Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventor: Gerald W. Fischer
  • Patent number: 7241592
    Abstract: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 10, 2007
    Assignees: Universita Degli Studi di Pavia, The Texas A&M University System, Inhibitex, Inc.
    Inventors: Magnus Hook, Yi Xu, Pietro Speziale, Livia Visal, Fabrizia Casolini, Joseph M. Patti, Pratiksha Patel, Paul Domanski
  • Patent number: 7238351
    Abstract: The method of producing a microbial adherence inhibitor for administration to food animals to control the incidents of acidosis in food animals by preventing the adherence of colony-forming lactic acid producing bacteria in the rumen or intestinal tracts of the food animals. The method includes inoculating female birds in or about their egg laying age with a lactic acid producing bacteria that colonizes in the intestinal tract of the food animal to be treated. Allowing a period of time sufficient to permit the production in the birds of antibody to the lactic acid producing bacteria and harvesting the eggs laid by such birds. The antibody-containing contents of the eggs are then separated by the shells.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: July 3, 2007
    Inventors: Peter Nash, Bradley M. Mitteness
  • Patent number: 7226590
    Abstract: This invention provides novel Streptococcus salivarius, compositions containing same, and use of S. salivarius strains as antimicrobial agents. The strains are bacterial inhibitors with respect to at least S. mutans and/or MS and therefore have a number of therapeutic applications. The applications include but are not limited to forming part of therapeutic formulations for use in controlling, treating, or preventing dental caries.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: June 5, 2007
    Assignee: BLIS Technologies Limited
    Inventors: Christopher Norman Chilcott, John Robert Tagg
  • Patent number: 7195763
    Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAVVEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: March 27, 2007
    Assignee: The Texas A & M Univerisity System
    Inventors: Yi Xu, Magnus A. O. Hook
  • Patent number: 7189404
    Abstract: The present invention relates to vaccine composition(s) comprising at least two PspAs from strains selected from at least one family, the family being defined by PspAs from strains belonging to the family having greater than or equal to 50% homology in aligned sequences of a C-terminal region of an alpha helical region of PspA. Additionally, the families are further comprised of clades, wherein PspAs from strains which belong to a clade exhibit greater than 75% sequence homology in aligned sequences of the C-terminal region of the alpha helix of PspA. Vaccine compositions of the present invention preferably comprise a minimum of 4 and a maximum of 6 strains representing a single clade each, and the at least two PspAs are optionally serologically or broadly cross-reactive.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: March 13, 2007
    Assignee: The UAB Research Foundation
    Inventors: Robert S. Becker, David E. Briles, Susan Hollingshead
  • Patent number: 7183083
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: February 27, 2007
    Assignee: Wyeth
    Inventors: Lynn Doucette-Stamm, David Bush
  • Patent number: 7160990
    Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: January 9, 2007
    Assignee: Biostapro AB
    Inventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
  • Patent number: 7115264
    Abstract: Monoclonal antibodies which can bind to the Fnbp protein of Staphylococcus aureus and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of S. aureus are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. The monoclonal antibodies of the invention are advantageous in that they bind S. aureus in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of S. aureus Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: October 3, 2006
    Assignee: INHIBITEX
    Inventors: Joseph M. Patti, Pratisksha Patel, Andrea Hall, Paul Domanski, Peter Syribeys, Jeff T. Hutchins
  • Patent number: 7087228
    Abstract: The present invention provides compositions, medicaments, and methods for the treatment or prophylaxis of conditions associated with the binding of Streptococcus mutans to teeth. Specifically, the present invention provides a method for preventing dental caries and infective endocarditis in a subject by treating the subject's oral cavity with a composition or medicament comprising the competence stimulating peptide (CSP) of the causative bacterium, which inhibits the ability of the said bacteria to attach to the surface of teeth. Novel anti-caries compositions using the CSP are also disclosed.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: August 8, 2006
    Assignee: University of Southern California
    Inventors: Steven D. Goodman, Olga Kay
  • Patent number: 7078042
    Abstract: Disclosed and claimed are: epitopic regions of Pneumococcal Surface Protein C or “PspC”, different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, e.g., to detect the presence of PspC or of S. pneumoniae by detecting a nucleic acid molecule therefor in a sample such as by amplification and/or a polymerase chain reaction, vectors or plasmids which contain and/or express such nucleic acid molecles, e.g.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: July 18, 2006
    Assignee: UAB Research Foundation
    Inventors: David E. Briles, Susan K. Hollingshead, Alexis Brooks-Walter
  • Patent number: 7067135
    Abstract: The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, Staphylococcus spp., particularly S. aureus.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: June 27, 2006
    Inventor: Naomi Balaban
  • Patent number: 7063980
    Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of mutans streptococci by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of mutans streptococci in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and mutans streptococci from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: June 20, 2006
    Assignee: GC Corporation
    Inventor: Atsushi Tachino
  • Patent number: 7056510
    Abstract: The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneunoniae. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of Streptococcus pneumoniae. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting Streptococcus nucleic acids, polypeptides and antibodies in a biological sample.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: June 6, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Gil H. Choi, Charles A. Kunsch, Steven C. Barash, Patrick J. Dillon, Brian Dougherty, Michael R. Fannon, Craig A. Rosen
  • Patent number: 7045131
    Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: May 16, 2006
    Assignee: Inhibitex, Inc.
    Inventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
  • Patent number: 7045132
    Abstract: The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: May 16, 2006
    Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, c/o Centers for Disease Control and Prevention
    Inventors: Jacquelyn Sampson, Harold Russell, Jean A. Tharpe, Edwin W. Ades, George M. Carlone
  • Patent number: 7030101
    Abstract: Compositions and kits comprising combinations of ?-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which ?-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: April 18, 2006
    Assignee: Nabi Biopharmaceuticals
    Inventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
  • Patent number: 7018986
    Abstract: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: March 28, 2006
    Assignee: Immudyne
    Inventors: Nino Sorgente, Harald L. Guenther, Hannelore E. Guenther, Arun K. Bahl
  • Patent number: 7015007
    Abstract: A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a gonoral method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymoric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: March 21, 2006
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Gerald B. Pier
  • Patent number: 6994855
    Abstract: The invention relates to the isolation of the fibrinogen binding protein gene from Staphylococcus aureus and to the use of the fibrinogen binding protein and antibodies generated against it for wound healing, blocking adherence to indwelling medical devices, immunization or diagnosis of infection.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: February 7, 2006
    Assignee: The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin
    Inventors: Timothy James Foster, Damien Leo McDevitt
  • Patent number: 6979446
    Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.
    Type: Grant
    Filed: January 28, 2002
    Date of Patent: December 27, 2005
    Assignee: Inhibitex, Inc.
    Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
  • Patent number: 6923962
    Abstract: The invention relates to a compound that competitively inhibits binding of CSP to S. mutans histidine kinase. The compound is preferably a peptide or an antibody. The compound is preferably a derivative of [SEQ ID NO:2], a fragment of [SEQ ID NO:2] or a derivative of a fragment of [SEQ ID NO:2].
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: August 2, 2005
    Inventors: Dennis Cvitkovitch, Peter C. Y. Lau, Yung Hua Li
  • Patent number: 6908619
    Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: June 21, 2005
    Assignee: University of Saskatchewan
    Inventors: Min Jiang, Andrew A. Potter, Philip Ronald MacLachlan
  • Patent number: 6841154
    Abstract: Polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus, are provided which can recognize surface proteins from both coagulase-positive and coagulase negative staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, and these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided vaccines and methods which utilize these proteins and antibodies for the treatment or protection against a wide variety of staphylococcal infections.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: January 11, 2005
    Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, Universita'degli Studi di Pavia
    Inventors: Timothy Foster, Fiona Roche, Mark Pallen, Joseph M. Patti, Jeff T. Hutchins, Pietro Speziale
  • Patent number: 6835818
    Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: December 28, 2004
    Assignee: Regents of the University of Minnesota
    Inventors: Patrick M. Schlievert, Douglas Ohlendorf, David T. Mitchell, Pamala J. Gahr
  • Publication number: 20040223973
    Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.
    Type: Application
    Filed: June 10, 2004
    Publication date: November 11, 2004
    Applicant: The Gov. of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
  • Patent number: 6803035
    Abstract: A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: October 12, 2004
    Assignee: Arkion Life Sciences
    Inventors: Hellen Chaya Greenblatt, Orn Adalsteinsson, David A. Brodie, Henry Jacoby
  • Patent number: 6790661
    Abstract: The invention provides methods for screening for the presence of a clinically relevant amount of bacteria in donor blood or a blood product from a donor mammal, particularly blood or a blood product that will be transferred from the donor mammal to a recipient mammal. The method comprises contacting a sample of the donor blood or a blood product with a set of binding agents that comprises binding agents that specifically bind to Gram-negative bacterial antigen and/or binding agents that specifically bind to Gram-positive bacterial antigen, and determining binding of the set of binding agents to the sample, wherein binding indicates the presence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product and no binding indicates the absence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: September 14, 2004
    Assignee: Verax Biomedical, Inc.
    Inventor: Timothy T. Goodnow
  • Patent number: 6790448
    Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAWEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: September 14, 2004
    Assignee: The Texas A&M University System University
    Inventors: Yi Xu, Magnus A. O. Hook
  • Patent number: 6790446
    Abstract: The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonization in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of Campylobacter jejuni protein after incubation of said Western blot with antibodies against a flagellaless mutant of Campylobacter jejuni and not visible after incubation of said blot with antibodies against wild type Campylobacter jejuni, and to their use in vaccines and the manufacturing thereof. The invention further relates to vaccines comprising such proteins and antibodies against such proteins. The invention further relates to the use of such Campylobacter proteins and to antiserum and antibodies raised against Campylobacter antigens for the preparation of vaccines. Finally, the invention relates to methods for the preparation of such vaccines.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: September 14, 2004
    Assignee: Akzo Nobel, NV
    Inventors: Antonius Arnoldus Christiaan Jacobs, Johannes Franciscus van den Bosch, Petrus Johannes Maria Nuijten